糖性专候选物质EQA材料的可交换性评价
Rui Wu1,2, Huijuan Zhou3, Xiaerbanu Nizhamnuding1,2
1National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, P.R. China.
Clinical chemistry and laboratory medicine
|May 29, 2025
概括
糖化白蛋白 (GA) 测量的一致性是一个挑战. 聚合血清样本cRM2在大多数酶套件中表现出可交换性,使其成为外部质量评估 (EQA) 计划的潜在候选人.
科学领域:
- 临床化学 临床化学
- 实验室医学 实验室医学
- 生物标记分析 生物标记分析
背景情况:
- 糖化白蛋白 (GA) 是监测糖尿病和控制血糖的关键生物标志物.
- 在不同的实验室检测系统中确保GA结果的一致性是一个重大挑战.
研究的目的:
- 评估10个样本的可交换性,以确定适合的外部质量评估 (EQA) 材料来测量糖性专蛋白 (GA).
- 用临床和实验室标准研究所 (CLSI) 和国际临床化学和实验室医学联合会 (IFCC) 的方法比较通用性评估.
主要方法:
- 采用同位素稀释液体色谱-并联质谱法 (ID LC-MS/MS) 作为参考方法.
- 评估了六个商业酶套件用于GA的确定.
- 根据CLSI EP14-A3和IFCC协议评估了临床样本,妊娠样本和评估样本的可换性.
主要成果:
- 使用CLSI方法,聚合血清样本 (cRM1-3),特别是中度的cRM2,在6个评估套件中的5个中显示出可交换性.
- 根据IFCC的方法,在评估组中没有发现任何可交换的样本.
结论:
- 关于样本可交换性,CLSI和IFCC的评估方法产生了不同的结果.
- 聚合血清样本cRM2在大多数酶性GA套件中表现出可交换性,使其成为EQA方案的可行的候选人.
相关概念视频
Sugars as Energy Storage Molecules
Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...


